These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20458811)

  • 1. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir--the ARTEN Study.
    Sax PE
    J Watch AIDS Clin Care; 2009 Oct; 21(10):80. PubMed ID: 20458811
    [No Abstract]   [Full Text] [Related]  

  • 2. Report from the 13th retrovirus conference. Extending the role of atazanavir.
    Feinberg J
    AIDS Clin Care; 2006 Apr; 18(4):38. PubMed ID: 16718882
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
    TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-HIV agents. The Castle study: lopinavir vs. atazanavir.
    TreatmentUpdate; 2008 Mar; 20(2):7-8. PubMed ID: 18661646
    [No Abstract]   [Full Text] [Related]  

  • 5. Report from the 2008 joint ICAAC/IDSA meeting. Darunavir and atazanavir: 96-week data from ARTEMIS and CASTLE.
    Sax PE
    AIDS Clin Care; 2008 Dec; 20(12):98. PubMed ID: 19271333
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
    Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
    Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.
    Horberg M; Klein D; Hurley L; Silverberg M; Towner W; Antoniskis D; Kovach D; Mogyoros M; Blake W; Dobrinich R; Dodge W
    HIV Clin Trials; 2008; 9(6):367-74. PubMed ID: 19203902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.
    Poirier JM; Guiard-Schmid JB; Meynard JL; Bonnard P; Zouai O; Lukiana T; Jaillon P; Girard PM; Pialoux G
    AIDS; 2006 Apr; 20(7):1087-9. PubMed ID: 16603872
    [No Abstract]   [Full Text] [Related]  

  • 9. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
    Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HIV agents. Atazanavir and saquinavir.
    TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
    Giuntini R; Martinelli C; Ricci E; Vichi F; Gianelli E; Madeddu G; Abeli C; Palvarini L; Penco G; Marconi P; Grosso C; Pellicano G; Bonfanti P; Quirino T
    HIV Med; 2010 Jan; 11(1):40-5. PubMed ID: 19686438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising new agents on the horizon.
    Feinberg J
    AIDS Clin Care; 2002 Mar; 14(3):22. PubMed ID: 12141239
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users.
    Lima VD; Nosyk B; Wood E; Kozai T; Zhang W; Chan K; Montaner JS
    AIDS; 2012 Jul; 26(12):1491-500. PubMed ID: 22555161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atazanavir: clinical use.
    Bartlett JG
    Hopkins HIV Rep; 2003 Jul; 15(4):3-4. PubMed ID: 14696561
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug profile: atazanavir (Reyataz, ATV).
    Pham PA
    Hopkins HIV Rep; 2003 Jul; 15(4):4-5. PubMed ID: 14696562
    [No Abstract]   [Full Text] [Related]  

  • 18. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
    Cordery DV; Hesse K; Amin J; Cooper DA
    Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Atazanavir--booster of the future?
    TreatmentUpdate; 2003; 15(3):5-6. PubMed ID: 17219613
    [No Abstract]   [Full Text] [Related]  

  • 20. [Nevirapine (Viramune): a new HIV inhibitor].
    De Wit S; Sternon J; Clumeck N
    Rev Med Brux; 1999 Apr; 20(2):95-9. PubMed ID: 10335104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.